Concepts (71)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Granuloma, Plasma Cell | 1 | 2020 | 2 | 0.630 |
Why?
|
| Proctitis | 1 | 2020 | 6 | 0.630 |
Why?
|
| Herpesvirus 2, Human | 1 | 2020 | 14 | 0.630 |
Why?
|
| Herpes Simplex | 1 | 2020 | 49 | 0.610 |
Why?
|
| Herpesvirus 1, Human | 1 | 2020 | 83 | 0.600 |
Why?
|
| Rectum | 1 | 2020 | 97 | 0.600 |
Why?
|
| Endothelium, Vascular | 1 | 2020 | 177 | 0.580 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 708 | 0.450 |
Why?
|
| HIV Infections | 1 | 2020 | 957 | 0.380 |
Why?
|
| Prostatic Neoplasms | 2 | 2026 | 498 | 0.330 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2026 | 58 | 0.230 |
Why?
|
| Thiolester Hydrolases | 1 | 2025 | 10 | 0.230 |
Why?
|
| Stromal Cells | 1 | 2026 | 78 | 0.230 |
Why?
|
| Immunologic Surveillance | 1 | 2025 | 22 | 0.230 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2025 | 46 | 0.220 |
Why?
|
| Cellular Senescence | 1 | 2026 | 121 | 0.220 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2025 | 169 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2025 | 113 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2025 | 234 | 0.200 |
Why?
|
| Ovarian Neoplasms | 1 | 2025 | 170 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2025 | 314 | 0.200 |
Why?
|
| Hematoxylin | 1 | 2022 | 11 | 0.190 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2022 | 12 | 0.190 |
Why?
|
| Endosonography | 1 | 2022 | 27 | 0.180 |
Why?
|
| Cytodiagnosis | 1 | 2022 | 46 | 0.180 |
Why?
|
| Membrane Proteins | 1 | 2025 | 924 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 62 | 0.150 |
Why?
|
| Endothelial Cells | 1 | 2020 | 213 | 0.140 |
Why?
|
| Antiviral Agents | 1 | 2020 | 326 | 0.130 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 2492 | 0.110 |
Why?
|
| Immunotherapy | 2 | 2025 | 274 | 0.100 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 1567 | 0.080 |
Why?
|
| Sensory Receptor Cells | 1 | 2011 | 21 | 0.080 |
Why?
|
| Long-Term Potentiation | 1 | 2011 | 42 | 0.080 |
Why?
|
| Amygdala | 1 | 2011 | 85 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 80 | 0.080 |
Why?
|
| Male | 5 | 2026 | 31187 | 0.080 |
Why?
|
| Humans | 5 | 2026 | 65463 | 0.080 |
Why?
|
| Synaptic Transmission | 1 | 2011 | 151 | 0.080 |
Why?
|
| Mice | 4 | 2026 | 11138 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2020 | 5806 | 0.070 |
Why?
|
| Pain | 1 | 2011 | 400 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2025 | 22 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2025 | 3155 | 0.060 |
Why?
|
| Animals | 4 | 2026 | 21381 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 183 | 0.050 |
Why?
|
| Middle Aged | 1 | 2020 | 18387 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2025 | 586 | 0.050 |
Why?
|
| Disease Progression | 1 | 2026 | 1223 | 0.040 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2011 | 6 | 0.020 |
Why?
|
| Phorbol Esters | 1 | 2011 | 4 | 0.020 |
Why?
|
| Tetrodotoxin | 1 | 2011 | 11 | 0.020 |
Why?
|
| Sodium Channel Blockers | 1 | 2011 | 12 | 0.020 |
Why?
|
| Afferent Pathways | 1 | 2011 | 16 | 0.020 |
Why?
|
| Acids | 1 | 2011 | 14 | 0.020 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2011 | 46 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2011 | 133 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2011 | 139 | 0.020 |
Why?
|
| Ventral Tegmental Area | 1 | 2011 | 38 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2011 | 126 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 129 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 491 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 343 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 857 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 367 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 962 | 0.020 |
Why?
|
| Female | 2 | 2025 | 34193 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 787 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3488 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 2305 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 3774 | 0.010 |
Why?
|